

Third-quarter biotech job picture



A quarterly snapshot of job expansions, reductions and availability in the biotech and pharma sectors.

Expansion continued across the biopharma industry in the third quarter of 2022. In the Boston area, Eli Lilly plans to lease 334,000 square feet for its recently launched Institute for Genetic Medicine. Takeda leased 600,000 square feet for an R&D site in Kendall Square, and AstraZeneca is readying a site in Cambridge for 1,500 employees of its Alexion subsidiary. Not all the news was good, however. Biogen will lay off 1,000 employees to shave

\$1 billion in costs owing to disappointing sales of its Alzheimer's drug, Aduhelm (aducanumab).

WuXi AppTec has broken ground on a site in Middletown, Delaware for its contract research and manufacturing subsidiary WuXiSTA. The 190-acre plant will be the company's second in the US and will create 500 positions by 2026. And ThermoFisher has opened a \$105 million, 400,000-square-foot manufacturing facility near Nashville, Tennessee, part of a \$650 million investment to build sites across the US, UK and China in 2022.

In Europe, Merck KGaA continued its expansion by announcing a \$127-million investment to increase the production of COVID-19 vaccines and other therapeutics at its site in Molsheim, France. The investment aims to create 800 jobs in the next six years. "This investment is an integral component of our plans to expand our global manufacturing footprint and deliver superior customer value across the globe," said Belén Garijo, CEO.

AbbVie announced it will lay off 99 employees from an Allergan manufacturing site in Irvine, California. AbbVie bought Allergan for \$63 billion in 2019. Finally, Bristol Myers Squibb will lay off 261 employees in San Diego as part of its acquisition of Turning Point Therapeutics.

Advertised biotechnology and pharmaceutical sector jobs in the job databases tracked by *Nature Biotechnology* rose sharply in the third quarter of 2022 (Tables 1 and 2) compared with the previous quarter (*Nat. Biotechnol.* **40**, 1299, 2022).

Table 1 | Who's hiring? Advertised openings at the 25 largest biotech companies

Company ^a	Number of employees	Number of advertised openings ^b		
		Indeed	LinkedIn	Biospace
Novo Nordisk	44,723	532	1,351	0
CSL	25,000	5,906	5,704	0
Amgen	24,300	1,081	576	702
Grifols	23,668	726	781	0
Gilead Sciences	13,600	538	867	704
Biocon	13,500	0	6	0
bioMérieux	12,800	104	195	0
IDEXX	9,300	165	298	0
Regeneron Pharmaceuticals	9,123	587	973	595
Biogen	9,100	197	310	0
Illumina	7,800	105	177	0
Novozymes	5,903	15	61	0
BeiGene	5,300	96	857	0
Opko Health	5,269	2	0	0
Exact Sciences	4,800	137	264	0
GenScript	4,601	44	38	0
Alexion Pharmaceuticals	3,837	250	501	0
BGI Genomics	3,778	5	37	0
Evotec	3,572	92	435	64
Vertex Pharmaceuticals	3,400	294	365	0
Endo Pharmaceuticals	3,397	32	1	0
Innovent Biologics	3,279	1	3	0
BioMarin Pharmaceutical	3,059	74	97	74
Gan & Lee Pharmaceuticals	2,934	5	26	0
Myriad Genetics	2,600	90	86	0
Total		11,078	14,009	2,139

^aAs defined in *Nature Biotechnology's* survey of public companies (<https://doi.org/10.1038/s41587-021-00973-w>). ^bAs searched on Indeed.com, LinkedIn.com and Biospace.com, 3 October 2022. Jobs may overlap.

Table 2 | Advertised job openings at the ten largest pharma companies

Company ^a	Number of employees	Number of advertised openings ^b		
		Indeed	LinkedIn	Biospace
Johnson & Johnson	134,500	1,805	4,208	0
Abbott Laboratories	109,000	803	2,348	493
Novartis	109,000	457	1,696	0
Roche	101,500	284	2,244	0
Bayer	99,400	768	1,864	0
Sanofi	99,400	1,164	2,100	1
GSK	94,100	1,012	3,000	0
Pfizer	78,500	660	2,820	686
AstraZeneca	76,100	885	1,962	0
Merck & Co.	74,000	885	668	0
Total		8,723	22,910	1,180

^aData obtained from Statista. ^bAs searched on Indeed.com, LinkedIn.com and Biospace.com, 3 October 2022. Jobs may overlap.

Michael Francisco
Senior Editor, *Nature Biotechnology*.

Published online: 8 November 2022